Literature DB >> 24293261

Gastrodin ameliorates depressive-like behaviors and up-regulates the expression of BDNF in the hippocampus and hippocampal-derived astrocyte of rats.

Ruiguo Zhang1, Zhengwu Peng, Huaihai Wang, Fen Xue, Yihuan Chen, Ying Wang, Huaning Wang, Qingrong Tan.   

Abstract

Gastrodin (GAS), a main constituent of a Chinese herbal medicine Tian ma, has been shown to be effective in treating various mood disorders. The purpose of the present study was to assess the effects of GAS on alleviating depressive-like behaviors in a rat model of chronic unpredictable stress (CUS) and regulating the expression of BDNF in the hippocampus and hippocampal-derived astrocyte from Sprague-Dawley (SD) rats. Following CUS, rats were intraperitoneally administered gastrodin (50, 100, or 200 mg/kg daily) or vehicle for 2 weeks. Rats were then experienced sucrose preference test and forced swim test. The expressions of GFAP and BDNF in the hippocampus were evaluated. In addition, hippocampal astrocytes were isolated from neonatal SD rats and exposed to different concentrations of GAS (sham, 5, 10, 20, 50 and 100 μg/mL) for 48 and 72 h before the cell viability and the levels of pERK1/2 and BDNF were analyzed. Furthermore, the cell viability was also tested after exposure to serum-free condition that contain different concentrations of GAS for 48 and 72 h. GAS administration (100 and 200 mg/kg daily) reversed depressive-like behaviors in rats exposed to CUS paradigm and restored the expression of GFAP and BDNF in the hippocampus. Moreover, in vitro experiments revealed that GAS did not increase the cell viability of astrocytes but protected it from 72 h's serum-free damage at the dosage 20 μg/mL. Increased levels of ERK1/2 phosphorylation and BDNF protein were also observed after GAS (20 μg/mL) treatment for 72 h. These results indicate that gastrodin possesses antidepressant effect. The changes of the astrocyte activation and the level of BDNF may play a critical role in the pharmacological action of GAS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24293261     DOI: 10.1007/s11064-013-1203-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

Review 1.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

Review 2.  Reactive astrocytes: cellular and molecular cues to biological function.

Authors:  J L Ridet; S K Malhotra; A Privat; F H Gage
Journal:  Trends Neurosci       Date:  1997-12       Impact factor: 13.837

3.  Time-dependent changes in BDNF expression of pentylenetetrazole-induced hippocampal astrocytes in vitro.

Authors:  Hao Zhu; Ming-Feng Chen; Wen-Juan Yu; Wen-Jin Wang; Feng Li; Wen-Chao Liu; Yan Wo; Rong Xia; Wen-Long Ding
Journal:  Brain Res       Date:  2011-12-24       Impact factor: 3.252

Review 4.  Stress, depression, and anhedonia: caveats concerning animal models.

Authors:  Hymie Anisman; Kim Matheson
Journal:  Neurosci Biobehav Rev       Date:  2005-04-22       Impact factor: 8.989

Review 5.  Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice.

Authors:  T Deltheil; B P Guiard; J Cerdan; D J David; K F Tanaka; C Repérant; J-P Guilloux; F Coudoré; R Hen; A M Gardier
Journal:  Neuropharmacology       Date:  2008-08-12       Impact factor: 5.250

6.  Anxiolytic-like effects of Gastrodia elata and its phenolic constituents in mice.

Authors:  Ji Wook Jung; Byung Hoon Yoon; Hye Rim Oh; Jae-Hyeong Ahn; Sun Yeou Kim; Sang-Yong Park; Jong Hoon Ryu
Journal:  Biol Pharm Bull       Date:  2006-02       Impact factor: 2.233

7.  Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat.

Authors:  Mounira Banasr; Gerald W Valentine; Xiao-Yuan Li; Shannon L Gourley; Jane R Taylor; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2007-06-21       Impact factor: 13.382

Review 8.  Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods.

Authors:  Marcelo T Berlim; Gustavo Turecki
Journal:  Can J Psychiatry       Date:  2007-01       Impact factor: 4.356

9.  Pharmacokinetics of gastrodin and its metabolite p-hydroxybenzyl alcohol in rat blood, brain and bile by microdialysis coupled to LC-MS/MS.

Authors:  Lei-Chwen Lin; Yen-Fei Chen; Wen-Chuan Lee; Yu-Tse Wu; Tung-Hu Tsai
Journal:  J Pharm Biomed Anal       Date:  2008-07-29       Impact factor: 3.935

10.  Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice.

Authors:  Eleni Païzanis; Thibault Renoir; Vincent Lelievre; Françoise Saurini; Maxette Melfort; Cecilia Gabriel; Nicholas Barden; Elisabeth Mocaër; Michel Hamon; Laurence Lanfumey
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-24       Impact factor: 5.176

View more
  19 in total

1.  Gastrodin alleviates cerebral ischemic damage in mice by improving anti-oxidant and anti-inflammation activities and inhibiting apoptosis pathway.

Authors:  Zhengwu Peng; Shiquan Wang; Guanjie Chen; Min Cai; Rui Liu; Jiao Deng; Jiangzheng Liu; Tao Zhang; Qingrong Tan; Chunxu Hai
Journal:  Neurochem Res       Date:  2015-01-13       Impact factor: 3.996

2.  Gastrodin Reduces the Severity of Status Epilepticus in the Rat Pilocarpine Model of Temporal Lobe Epilepsy by Inhibiting Nav1.6 Sodium Currents.

Authors:  Hui Shao; Yang Yang; Ai-Ping Qi; Pian Hong; Guang-Xi Zhu; Xin-Yu Cao; Wei-Gang Ji; Zhi-Ru Zhu
Journal:  Neurochem Res       Date:  2016-10-14       Impact factor: 3.996

3.  Repetitive transcranial magnetic stimulation inhibits Sirt1/MAO-A signaling in the prefrontal cortex in a rat model of depression and cortex-derived astrocytes.

Authors:  Zheng-Wu Peng; Fen Xue; Cui-Hong Zhou; Rui-Guo Zhang; Ying Wang; Ling Liu; Han-Fei Sang; Hua-Ning Wang; Qing-Rong Tan
Journal:  Mol Cell Biochem       Date:  2017-09-25       Impact factor: 3.396

4.  Brain-derived neurotrophic factor and interleukin-6 levels in the serum and cerebrospinal fluid of children with viral infection-induced encephalopathy.

Authors:  Shinichiro Morichi; Gaku Yamanaka; Yu Ishida; Shingo Oana; Yasuyo Kashiwagi; Hisashi Kawashima
Journal:  Neurochem Res       Date:  2014-08-15       Impact factor: 3.996

Review 5.  Microglia: An Interface between the Loss of Neuroplasticity and Depression.

Authors:  Gaurav Singhal; Bernhard T Baune
Journal:  Front Cell Neurosci       Date:  2017-09-08       Impact factor: 5.505

Review 6.  Brain-Derived Neurotrophic Factor, Depression, and Physical Activity: Making the Neuroplastic Connection.

Authors:  Cristy Phillips
Journal:  Neural Plast       Date:  2017-08-08       Impact factor: 3.599

7.  Effects of Bu Shen Yi sui capsule on NogoA/NgR and its signaling pathways RhoA/ROCK in mice with experimental autoimmune encephalomyelitis.

Authors:  Ling Fang; Yongqiang Wang; Qi Zheng; Tao Yang; Peiyuan Zhao; Hui Zhao; Qiuxia Zhang; Yuanyuan Zhao; Fang Qi; Kangning Li; Zhenzhen Chen; Junling Li; Nan Zhang; Yongping Fan; Lei Wang
Journal:  BMC Complement Altern Med       Date:  2017-07-01       Impact factor: 3.659

8.  The efficacy of gastrodin in combination with folate and vitamin B12 on patients with epilepsy after stroke and its effect on HMGB-1, IL-2 and IL-6 serum levels.

Authors:  Hao Zhou; Nuan Wang; Lei Xu; Hongli Huang; Chunyu Yu
Journal:  Exp Ther Med       Date:  2017-09-14       Impact factor: 2.447

Review 9.  A Review on Central Nervous System Effects of Gastrodin.

Authors:  Yuan Liu; Jialiang Gao; Min Peng; Hongyan Meng; Hongbo Ma; Pingping Cai; Yuan Xu; Qiong Zhao; Guomin Si
Journal:  Front Pharmacol       Date:  2018-02-02       Impact factor: 5.810

10.  Gastrodin Attenuates Bilateral Common Carotid Artery Occlusion-Induced Cognitive Deficits via Regulating Aβ-Related Proteins and Reducing Autophagy and Apoptosis in Rats.

Authors:  Bo Liu; Jian-Mei Gao; Fei Li; Qi-Hai Gong; Jing-Shan Shi
Journal:  Front Pharmacol       Date:  2018-04-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.